This Biotech Lost 95% in a Single Day. It Still Deserves Credit
Tricida only pursued a single drug candidate. That backfired spectacularly, but the drug developer deserves credit on one key measure. Many investors incorrectly assume that drug d…
Tricida only pursued a single drug candidate. That backfired spectacularly, but the drug developer deserves credit on one key measure. Many investors incorrectly assume that drug d…